^
Association details:
| Biomarker: | ERBB3 overexpression |
|---|---|
| Cancer: | Colorectal Cancer |
| Drug: | Vectibix (panitumumab) (EGFR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Clinical and molecular characteristics and treatment outcomes of advanced right-colon, left-colon and rectal cancers: data from 1180 patients in a phase III trial of panitumumab with an extended biomarker panel
Published date:
05/11/2020
Excerpt:
aCRC patients from the second-line PICCOLO trial of irinotecan versus irinotecan/panitumumab. PTL was classified as right-PTL, left-PTL or rectal-PTL….High HER3 expression was independently predictive of panitumumab OS improvement…Patients with right-PTL and high EREG/AREG or HER3 expression, had IrPan PFS improvement (high EREG/AREG HR=0.20, p=0.04; high HER3 HR=0.33, p=0.10) compared with irinotecan. Similar effect was seen for rectal-PTL patients (high EREG/AREG HR=0.44, p=0.03; high HER3 HR=0.34, p=0.05).
Secondary therapy:
irinotecan
DOI:
10.1016/j.annonc.2020.04.476
Source:
Title:
Association of Tumor HER3 Messenger RNA Expression With Panitumumab Efficacy in Advanced Colorectal Cancer
Excerpt:
Higher HER3 was predictive, being associated with prolonged PFS on irinotecan plus panitumumab (IrPan) (HR, 0.71; 95% CI, 0.61-0.82; P < .001), but not irinotecan (HR, 0.96; 95% CI, 0.82-1.13; P = .65) in patients with RAS wt, with significant interaction between biomarker and treatment (P = .001)
Secondary therapy:
irinotecan
DOI:
10.1001/jamaoncol.2017.3168.
Trial ID:
